Syndax Pharmaceuticals, Inc.

NasdaqGS:SNDX Stock Report

Market Cap: US$1.8b

Syndax Pharmaceuticals Future Growth

Future criteria checks 5/6

Syndax Pharmaceuticals is forecast to grow earnings and revenue by 61.9% and 33.8% per annum respectively while EPS is expected to grow by 61.7% per annum.

Key information

61.9%

Earnings growth rate

61.75%

EPS growth rate

Biotechs earnings growth23.2%
Revenue growth rate33.8%
Future return on equityn/a
Analyst coverage

Good

Last updated09 Dec 2025

Recent future growth updates

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Nov 06
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

May 08
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

Recent updates

Syndax Pharma: Continuing Execution In AML

Dec 17

Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up

Nov 23
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Nov 06
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking

Aug 06
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking

Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?

Aug 05
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

May 08
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?

Apr 26
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?
User avatar

FDA Approvals Will Expand AML And cGVHD Treatment Options

Recent FDA approvals and strategic collaborations position Syndax to significantly enhance revenue and address unmet clinical needs in oncology.

Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?

Feb 07
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?

Syndax Looks Tantalizing, But Looks Can Be Deceptive

Jan 22

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

NasdaqGS:SNDX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20287401261902416
12/31/2027564231918911
12/31/2026369-11955-5112
12/31/2025168-266-259-15412
9/30/2025111-312-311-311N/A
6/30/202578-335-303-303N/A
3/31/202544-331-287-287N/A
12/31/202424-319-275-275N/A
9/30/202416-297-259-259N/A
6/30/20244-264-241-241N/A
3/31/2024N/A-241-205-205N/A
12/31/2023N/A-209-161-161N/A
9/30/2023N/A-176-142-142N/A
6/30/2023N/A-160-126-126N/A
3/31/2023N/A-153-131-131N/A
12/31/2022N/A-149-134-134N/A
9/30/2022127-14-10-10N/A
6/30/20221391-7-6N/A
3/31/2022139151010N/A
12/31/2021140252929N/A
9/30/202114-92-87-87N/A
6/30/20212-91-81-81N/A
3/31/20212-86-78-78N/A
12/31/20202-77-71-71N/A
9/30/20202-71-68-68N/A
6/30/20202-63-59-59N/A
3/31/20202-61-50-50N/A
12/31/20192-56-51-51N/A
9/30/20192-61-53-53N/A
6/30/20192-65N/A-63N/A
3/31/20192-69N/A-65N/A
12/31/20182-74N/A-69N/A
9/30/20182-74N/A-66N/A
6/30/20182-72N/A-58N/A
3/31/20182-67N/A-55N/A
12/31/20172-61N/A-47N/A
9/30/20171-53N/A-45N/A
6/30/20171-52N/A-46N/A
3/31/20171-47N/A-41N/A
12/31/20161-47N/A-35N/A
9/30/20161-45N/A-29N/A
6/30/20161-87N/A-23N/A
3/31/20161-105N/A-20N/A
12/31/20151-104N/A-2N/A
9/30/20150-100N/A-2N/A
6/30/20150-53N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: SNDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SNDX is expected to become profitable in the next 3 years.

Revenue vs Market: SNDX's revenue (33.8% per year) is forecast to grow faster than the US market (10.4% per year).

High Growth Revenue: SNDX's revenue (33.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNDX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/02 07:36
End of Day Share Price 2025/12/31 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syndax Pharmaceuticals, Inc. is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBarclays
Jason ZemanskyBofA Global Research